|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
|
Luke Timmerman |
05/14/12 |
National
|
|
Boston Life Sciences News From Vertex, Eleven, RXi, & More
|
Erin Kutz |
05/11/12 |
Boston
|
|
SD Life Sciences Roundup: Celladon, Vertex, MediciNova, & More
|
Bruce V. Bigelow |
05/10/12 |
San Diego
|
|
IDRI, Aeras Team Up to Develop Tuberculosis Vaccine
|
Luke Timmerman |
05/09/12 |
Seattle
|
|
A 10-Point Plan to Stimulate Biotech & the Economy as a Whole
|
Ron Najafi |
05/09/12 |
National
|
|
NY’s Cancer Research Institute Looks to Boost Cancer Immunotherapy
|
Arlene Weintraub |
05/09/12 |
New York
|
|
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future
|
Luke Timmerman |
05/08/12 |
Seattle
|
|
San Diego’s MediciNova Nears Turning Point with Lead Drug for Asthma
|
Bruce V. Bigelow |
05/08/12 |
San Diego
|
|
San Diego’s Celladon Extends Round to $53M, Opens European Office
|
Bruce V. Bigelow |
05/08/12 |
San Diego
|
|
Sutro Biopharma Pulls in $16M for New Antibody Drugs
|
Luke Timmerman |
05/08/12 |
San Francisco
|
|
Eleven Biotherapeutics Raises $20M to Advance Dry-Eye Drug
|
Arlene Weintraub |
05/08/12 |
Boston
|
|
First Comes The $1,000 genome, Then Comes The $10,000 Analysis
|
Adina Mangubat |
05/08/12 |
Seattle
|
|
Dendreon Meets Expectations with $82M in 1st Quarter Provenge Sales
|
Luke Timmerman |
05/07/12 |
Seattle
|
|
Retrophin, Headed by Controversial Hedge Fund Chief, Raises $4M
|
Arlene Weintraub |
05/07/12 |
New York
|
|
Vertex Shares Boom on Cystic Fibrosis Results
|
Luke Timmerman |
05/07/12 |
Boston
|
|
Antibiotic R&D is in Trouble: Here’s One Way to Fix It
|
Luke Timmerman |
05/07/12 |
National
|
|
Analyst: Dendreon’s Growth Stalling With Cancer Docs as Rival Gains
|
Luke Timmerman |
05/04/12 |
Seattle
|
|
NIH’s Collins Lauds “Unprecedented” Partnership at NY Bio Confab
|
Arlene Weintraub |
05/04/12 |
New York
|
|
SD Life Sciences Roundup: Gen-Probe, Zogenix, & the Innovation Economy
|
Bruce V. Bigelow |
05/03/12 |
San Diego
|
|
Winners of “MI 50 Companies to Watch” Awards To Be Announced
|
Sarah Schmid |
05/03/12 |
Detroit
|
|
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill?
|
Stewart Lyman |
05/03/12 |
Seattle
|
|
Genomic Health, OncoMed Team Up on Personalized Cancer Drug Work
|
Luke Timmerman |
05/02/12 |
San Francisco
|
|
Boston Deals: Hologic, CustomMade, and the MIT Clean Energy Prize
|
Erin Kutz |
05/02/12 |
Boston
|
|
Pfizer Takes on Genzyme With New Gaucher Drug
|
Arlene Weintraub |
05/02/12 |
Boston
|
|
The Affymetrix Alumni: Where Are They Now?
|
Luke Timmerman |
05/02/12 |
San Francisco
|
|
5 Things to Do Before the New Patent Law Takes Full Effect
|
Ted Sichelman |
05/02/12 |
San Diego
|
|
Innovation Report Shows San Diego Added 695 Tech Jobs at End of 2011
|
Bruce V. Bigelow |
05/01/12 |
San Diego
|
|
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs
|
Arlene Weintraub |
05/01/12 |
Boston
|
|
Hologic Buys Gen-Probe for $3.7B, Making Molecular Diagnostics Push
|
Luke Timmerman |
04/30/12 |
Boston
|
|
Biotech IPOs Start to Show Some Modest Signs of Life
|
Luke Timmerman |
04/30/12 |
National
|
|
Page 2 of
189 |
« previous page · next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.